Eton Pharmaceuticals Inc. (NASDAQ: ETON) reported Q2 EPS of $0.43, $0.28 better than the analyst estimate of $0.15. Revenue for the quarter came in at $37.6 million versus the consensus estimate of $26.88 million.

GUIDANCE:

Eton Pharmaceuticals Inc. sees FY2026 revenue of $145 million, versus the consensus of $121 million.

For earnings history and earnings-related data on Eton Pharmaceuticals Inc. (ETON) click here.